All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Nabriva Therapeutics
Deal Size: $101.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement December 07, 2020
Details:
The restructured agreement provides for additional manufacturing collaboration and regulatory support [to be provided to Sinovant by Nabriva] that is expected to help expedite the delivery of XENLETA to patients in greater China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of poor outcomes
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
Nabriva Therapeutics has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tedizolid Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Sivextro
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 15, 2020
Details:
Under the terms of the agreement, Nabriva will procure SIVEXTRO from Merck & Co. Inc., Kenilworth, N.J., USA and be responsible for marketing, sales, and distribution of SIVEXTRO in the U.S. through December 31, 2023, with renewable three-year extensions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lefamulin Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xenleta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: WEP
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 06, 2020
Details:
Under the terms of the NPP, XENLETA will be made available in 2 formulations - 150mg injection for IV administration and 600mg oral tablets - using named patient or expanded access managed by WEP to enable healthcare professionals to access XENLETA to meet clinical needs.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
